Xigris Related Published Studies
Well-designed clinical trials related to Xigris (Drotrecogin Alfa)
Endogenous plasma activated protein C levels and the effect of enoxaparin and drotrecogin alfa (activated) on markers of coagulation activation and fibrinolysis in pulmonary embolism. [2011]
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). [2010]
A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial. [2008.01]
My brother has severe sepsis Should he receive Xigris(R)? [2007.12]
Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). [2007.09.01]
Drotrecogin alfa (activated) in the treatment of severe sepsis. [2007.09]
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. [2007.03.10]
Activated protein C (Xigris) treatment in sepsis: a drug in trouble. [2006.09]
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. [2005.09.29]
Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. [2005.03]
The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. [2004.11]
Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis. [2004.09]
Effects of drotrecogin alfa (activated) in human endotoxemia. [2004.03]
[Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain] [2004.01]
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. [2004.01]
Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. [2003.10]
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. [2003.09.15]
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results. [2003.09]
Drotrecogin alfa (activated) treatment of older patients with severe sepsis. [2003.07.15]
Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). [2003.07.01]
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. [2003.06]
Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. [2003.03]
Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis. [2003.02]
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. [2003.01]
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. [2003.01]
Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. [2002.10]
Tamsulosin: an update of its role in the management of lower urinary tract symptoms. [2002]
Well-designed clinical trials possibly related to Xigris (Drotrecogin Alfa)
Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis. [2011.10]
Influence of severity of illness on the effects of eritoran tetrasodium (E5564)
and on other therapies for severe sepsis. [2011]
Prowess-shock trial: a protocol overview and perspectives. [2010.09]
Activated protein C in severe acute pancreatitis without sepsis? Not just yet ... [2010]
APCAP--activated protein C in acute pancreatitis: a double-blind randomized human pilot trial. [2010]
Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without Streptococcus pneumoniae. [2009.08]
Effects of recombinant human activated protein C on the fibrinolytic system of patients undergoing conventional or tight glycemic control. [2009.07]
Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. [2009.01]
Current role of activated protein C therapy for severe sepsis and septic shock. [2008.09]
The effect of activated protein C on plasma cytokine levels in a porcine model of acute endotoxemia. [2007.06]
RESOLVE-ing sepsis in children--not yet! [2007]
Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome. [2006]
Comment to: Septic shock: current pathogenic concept from a clinical perspective Tsiotou AG, Sakorafas GH, Anagnostopoulos G, Bramis J Med Sci Monit, 2005; 11(3): RA76-RA85 Future treatment prespictives in septic shock. [2005.11.24]
Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis. [2005]
Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. [2004.12]
Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. [2004.11]
Evidence-based medicine in the ICU: important advances and limitations. [2004.08]
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. [2004.04]
Role of activated protein C in the pathophysiology of severe sepsis. [2003.11]
[Activated protein C--recent addition to therapy of sepsis] [2003.06.26]
Efficacy and safety of recombinant human activated protein C for severe sepsis. [2001.03.08]
Other research related to Xigris (Drotrecogin Alfa)
An updated meta-analysis to understand the variable efficacy of drotrecogin alfa
(activated) in severe sepsis and septic shock. [2013]
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice? [2011.09.26]
An unusual cause of multiple cerebral hemorrhages: drotrecogin alpha (activated protein C). [2011.05]
Successful treatment with drotrecogin alfa (activated) in a pregnant patient with severe sepsis. [2011.03]
Results from the National Sepsis Practice Survey: use of drotrecogin alpha (activated) and other therapeutic decisions. [2010.12]
A prospective, observational study of Xigris Use in the United States (XEUS). [2010.12]
The use of drotrecogin alpha for necrotizing soft tissue infections. [2010.10]
Clinical response to unintentionally rapid infusion of drotrecogin alfa (activated). [2010.07.15]
The use of drotrecogin alfa in severe falciparum malaria. [2010.07]
A prospective, observational study of Xigris Use in the United States (XEUS). [2010.04.30]
Reliability and accuracy of practitioner-calculated Acute Physiology and Chronic Health Evaluation II scores for determining the appropriateness of drotrecogin alfa (activated). [2010.01.15]
Interleukin-10 gene down-expression in circulating mononuclear cells during infusion of drotrecogin-alpha activated: a pilot study. [2010]
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock. [2010]
Drotrecogin alfa (activated) for severe sepsis: could we consider a shorter treatment period in patients with a favorable course? [2009.12]
Safety of drotrecogin alfa (activated) in severe sepsis: data from adult clinical trials and observational studies. [2009.12]
Evaluation of anti-activated protein C antibody development in patients with severe sepsis from four clinical studies with drotrecogin alpha (activated). [2009.11]
Pharmacologic modification to resuscitation fluid after thermal injury--is drotrecogin alfa the answer to arrest burn depth progression? [2009.11]
Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis. [2009.07]
Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. [2009.07]
Reversal of refractory septic shock with drotrecogin alpha (activated). [2009.07]
Treatment of Strongyloides stercoralis hyperinfection-associated septic shock and acute respiratory distress syndrome with drotrecogin alfa (activated) in a renal transplant recipient. [2009.06]
The use of drotrecogin alfa (activated) in solid organ transplant patients: a case series. [2009.06]
Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. [2009.01]
90-day follow-up of patients treated with Drotrecogin Alfa (activated) for severe sepsis: a Belgian open label study. [2009.01]
Errors in the approval process and post-marketing evaluation of drotrecogin alfa (activated) for the treatment of severe sepsis. [2009.01]
Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort. [2009]
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. [2009]
Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis. [2009]
Patient-specific decision modeling to guide the use of drotrecogin alpha (activated) in patients with severe sepsis. [2008.12]
Drotrecogin alfa's impact on intensive care workload in real life practice: a propensity score approach. [2008.12]
How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design. [2008.10]
Bleeding complications with Drotrecogin alfa activated (Xigris): a retrospective review of 31 operative and 68 non-operative patients with severe sepsis. [2008.10]
Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment? [2008.10]
Sepsis-related acute kidney injury: a protective effect of drotrecogin alpha (activated) treatment? [2008.10]
Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis. [2008.09.11]
Use of drotrecogin alfa in necrotizing fasciitis: a case report and pharmacologic review. [2008.09]
How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design. [2008.05.27]
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). [2008.04.04]
International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy. [2008.04]
Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice. [2008.03]
A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study. [2008.01]
A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units--an observational study. [2008.01]
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated). [2008]
Time-course of neopterin levels in patients suffering from severe sepsis treated with and without Drotrecogin-alpha (activated). [2008]
Drotrecogin alfa (activated): real-life use and outcomes for the UK. [2008]
Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis. [2008]
Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy. [2008]
Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice. [2007.11.22]
Drotrecogin alpha (activated): the treatment for severe sepsis? [2007.11]
Pasteurella multocida septic shock following liver transplantation treated with drotrecogin alpha (activated). [2007.09]
Effect of Drotrecogin alfa (activated) on platelet receptor expression in vitro. [2007.08]
Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis. [2007.06.25]
Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated). [2007.06.07]
|